Savelsbergh-Fillette M P, Demailly P
J Fr Ophtalmol. 1988;11(8-9):587-90.
Forty patients with chronic open-angle glaucoma or ocular hypertension participated in this randomized double-masked clinical trial. The patients instilled either 0.5% Levobunolol or 0.5% Timolol into each eye twice daily for three months. Levobunolol produced an overall decrease in mean intraocular pressure of approximately 7 mmHg, while Timolol produced an overall decrease of approximately 5 mmHg but no significant difference has been proved. Intraocular pressure was inadequately controlled in five patients in each treatment group. Both drugs caused heart rate decreases that were judged to be of limited clinical significance. Levobunolol was found to be as safe and effective as Timolol for the treatment of patients with open-angle glaucoma as for those with chronic ocular hypertension.
40例慢性开角型青光眼或高眼压症患者参与了这项随机双盲临床试验。患者每天两次向每只眼睛滴入0.5%的左布诺洛尔或0.5%的噻吗洛尔，持续三个月。左布诺洛尔使平均眼压总体下降约7 mmHg，而噻吗洛尔使平均眼压总体下降约5 mmHg，但尚未证实存在显著差异。每个治疗组均有5例患者的眼压控制不佳。两种药物均导致心率下降，但其临床意义有限。结果发现，对于开角型青光眼患者和慢性高眼压症患者，左布诺洛尔在治疗上与噻吗洛尔一样安全有效。
